Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Hadlima™ (adalimumab-bwwd) – New biosimilar strength approvall
August 17, 2022 - Samsung Bioepis and Organon announced the FDA approval of Hadlima (adalimumab-bwwd) citrate-free, high concentration (100 mg/mL) injection, biosimilar to AbbVie’s Humira® (adalimumab).
